Ophthalmology

In the study from AAO 2023, patients with neovascular AMD who are on aflibercept injection treatment continued their treatments >12 weeks or 16 weeks.

Patients with RAO had a higher risk of death, stroke, and myocardial infarction at both short-term and long-term intervals compared to matched controls diagnosed with cataract.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.

On October 27, 2023, the FDA warned consumers to stop using ophthalmic products from 6 brands, including CVS Health and Rite Aid, after investigators found bacterial contamination at a manufacturing facility.

Scleral buckling without PPV is effective for most patients with retinal dialysis and shows a low rate of cataract formation.

Most answers provided by ChatGPT-4 were consistently appropriate regarding vitreoretinal surgeries, including retinal detachments, macular holes, and epiretinal membranes.

Genentech announced the FDA had approved faricimab-svoa (Vabysmo) for retinal vein occlusion on October 26, 2023, which marks the third ophthalmic indication for the bispecific antibody.

Utilizing swept-source OCT, the analysis reports significantly thicker subfoveal choroidal thickness among patients with active disease than those with inactive disease.

Among an Egyptian cohort, isolated retinitis is the most common inherited retinal disease, followed by Stargardt, cone-rod dystrophy, autosomal recessive bestrophiniopathy, and the unspecified subtype.

Results revealed the inner lower and inner left subfields of the better eye were more strongly associated with vision-related quality of life than the worse eye.

An analysis of more than 700 videos on TikTok reveals new insight into the levels and purveyors of misinformation in the most popular ophthalmology content on the platform.

Many carriers reported feelings of concern, anxiousness, and guilt for passing the X-linked inherited retinal disease to their children—and 78% of respondents in a new study believe that carriers should have access to gene therapy options.

New data suggests retinal vein occlusion in individuals under 75 years of age correlates with increased dementia risk, while those older than 75 have a reduced risk.

Volume and frequency of alcohol consumption were associated with a greater risk of visual impairment and blindness among patients with newly diagnosed OAG.

In a new study, the effect of smoking did not impact treatment response of anti-VEGF injection for patients with neovascular age-related macular degeneration.

Healthy lifestyles, such as partaking in social-bonding activities, completing physical activity, and consuming healthy diets, all help reduce the onset and stop the progression of AM, as well as associated depression and loneliness.

New cross-sectional research indicates factors influencing ocular lesion status can include diabetes status, prednisolone dosage, and systemic infection status after kidney transplantation.

Results from the phase 3 NEAR-1 and NEAR-2 clinical trials show consistent efficacy and tolerability of the preservative-free, low-dose eye drop in patients with presbyopia.

A recent nationwide cohort study identified statistically significant associations between IBD and DED, as well as increased risks of corneal surface damage.

An analysis of 14 studies revealed that uveitis had an estimated prevalence of 3.27% in Crohn's disease and 1.60% in ulcerative colitis.

Adolescents from socioeconomically disadvantaged backgrounds were less likely to report receiving a vision test, particularly in clinical settings.

In a 12-month, real-world study, the implant was effective in more than half of eyes with non-infectious uveitis, achieving effectiveness as soon as 2 weeks post-implantation.

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

The latest episode of our mini-docuseries focuses on disparities in ophthalmology, from preventable vision impairment to gaps in access in underserved communities.